[Diagnosis of pancreatic cancer with simultaneous detection of a pancreatic-cancer-associated antigen and pancreas-specific antigen].
We reported the purification and characterization of a pancreatic cancer-associated antigen from normal colonic mucosa (PCAAc) and pancreas-specific antigen (PaA) according to Kitada's and Loor's methods as well as the established method of double antibody enzyme-linked immunoassay for the detection of serum PaA and PCAAc; respectively. In our study, 155 serum samples were detected (including normal controls 40; pancreatic cancer 31; other malignant disease 56 and benign diseases 28). The results indicated that the overall sensitivity and specificity of a single PCAAc test for pancreatic cancer were calculated to be 70.98% and 96.43%; a single PaA to be 80.65% and 95.23%, respectively. Furthermore, the sensitivity and specificity of combined tests (PCAAc and/or PaA) for pancreatic cancer were calculated to be 96.77% and 90.91%. The diagnostic efficiency was 90.91%. None of 84 cases of nonpancreatic cancer and benign diseases has been found elevated PCAAc and PaA simultaneously. The results suggest that simultaneous detection of PCAAc and PaA would have increased the sensitivity of diagnosis for pancreatic cancer.
Zhao
X Y
XY
Department of Medicine, Xing Qiao Hospital, Third Military Medical College, Chongqing.
Yu
S Y
SY
Bai
L
L
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C042317:DU-PAN-2 antigen, human; C019454:pancreas-specific antigen